Présentation de l'entreprise
Aditxt, Inc. operates as a commercial-stage biotechnology entity focused on the discovery and development of products within specialized domains including immune health, precision health, population health, women's health, and neurologic health. The company has engineered proprietary tools such as AditxtScore to assist individuals in understanding, managing, and monitoring their immune profiles, thereby bridging the gap between complex biological data and personal health management. Operating within the broader Healthcare sector and specifically the Biotechnology industry, the firm targets markets where advanced diagnostics and therapeutic interventions are critical for patient outcomes. With a market capitalization of $470,323 and annual revenue of $3,195, the company presents a micro-cap profile characterized by significant operational constraints relative to its peers. The extremely small market cap and minimal revenue figures indicate that Aditxt, Inc. functions as a speculative venture with limited commercial traction, suggesting that the entity is still in the early stages of establishing a sustainable revenue stream within the competitive biotechnology landscape.
Santé financière
The financial performance of Aditxt, Inc. is defined by a substantial disparity between its top-line revenue of $3,195 and its net income of -$43,101,452, a gap that reveals a cost structure heavily weighted toward research, development, and general administrative expenses that far exceed current sales generation. The company reports an EBITDA of -$19,301,452, indicating that even before financing costs and non-cash items, the core operations are generating negative cash equivalents. Free cash flow stands at -$18,098,088, which signifies a complete lack of financial flexibility, as the company must rely entirely on external capital sources to fund its day-to-day operations and strategic initiatives. Margin analysis highlights a gross margin of 8.4%, suggesting that the cost of goods sold consumes the majority of revenue, while the operating margin of -1098725.6% and profit margin of 0.0% reflect severe operational inefficiencies or one-time charges that have obliterated profitability. The balance sheet shows a cash position of $3.20M against total debt of $3.01M, resulting in a debt-to-equity ratio of 76.04, which technically indicates a leveraged position where debt exceeds equity, though the magnitude of the debt relative to the tiny equity base creates a precarious solvency profile. Liquidity is critically constrained by a current ratio of 0.31, meaning the company possesses less than one-third of the liquid assets required to cover its short-term liabilities without raising additional capital. Return on Equity is reported at -699.1% and Return on Assets at -50.3%, metrics that collectively reveal a management team facing immense challenges in deploying capital effectively to generate positive returns for shareholders or asset holders given the current financial trajectory.
Évaluation de la valorisation
Valuation metrics for Aditxt, Inc. present a complex picture due to the company's lack of profitability, with a trailing twelve-month P/E ratio listed as N/A and a forward P/E of -0.05, implying that earnings expectations are either non-existent or modeled in a way that does not support traditional multiple analysis. The price-to-book ratio is recorded as -0.00, a figure that typically indicates negative shareholder equity or accounting anomalies where the market value of the firm is theoretically below the net book value, suggesting a market discount that reflects high perceived risk. Alternative valuation measures such as the price-to-sales ratio of 147.21 and an EV/EBITDA of 0.07 further underscore the disconnect between current valuation multiples and fundamental earnings power, as the latter metric is heavily influenced by the massive negative EBITDA. The stock's price volatility is extreme, with a 52-week high of $3426.16 and a 52-week low of $0.50, indicating that the current trading price sits significantly below the historical high and fluctuates within a range that suggests high speculative interest or potential delisting concerns. The beta value of 1.40 confirms that the stock's price volatility is substantially higher than that of the broader market, moving 40% more than the average stock in response to market movements.
Growth & Income
Growth dynamics are characterized by a severe contraction in top-line performance, with revenue growth year-over-year declining by 86.6%, while earnings growth is listed as N/A due to the company's ongoing losses. This divergence, where earnings growth is unavailable and revenue is shrinking, implies that the company is not only failing to expand its market share but is also experiencing a rapid erosion of its existing customer base or commercial partnerships. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, Aditxt, Inc. does not distribute cash to shareholders, instead choosing to retain minimal cash reserves to attempt to fund future growth or operational survival. The overall growth and income profile is defined by negative momentum and an absence of shareholder returns, positioning the company as a high-risk investment vehicle that relies entirely on future product successes or capital injections to reverse its current trajectory of declining revenue and negative cash generation.